Latanoprost: Experience of 2‐year treatment in Scandinavia

Alm, Albert; Widengård, Ingmar

doi:10.1034/j.1600-0420.2000.078001071.x

Cited by 63 publications

(44 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PGF 2a -derivative ophthalmic solutions, including latanoprost solution, have been reported to cause an iris colour change and dark skin around the eye as side effects. [11][12][13][14][15][16][17][18][19][20] In cultured melanoma cells, a carboxylic acid of latanoprost has been reported to increase melanogenesis 31) and the results obtained in the present study confirm this report. However, the stimulatory effects on melanin content in cultured B16-F10 melanoma cells in our experiment did not correlate with the prostanoid FP-receptor agonistic activities of the 15,15-difluoro derivatives.…”

Section: Discussionsupporting

confidence: 82%

“…9,10) In addition, long-term application of PGF 2a derivatives causes chronic adverse effects, such as iris/skin pigmentation, eyelash growth, and so on. [10][11][12][13][14][15][16][17][18][19] The PGF 2a -derivative-induced eye colour change is most likely due to an increased amount of melanin within iris stroma melanocytes. [20][21][22] These adverse effects may be related to the stimulation of prostanoid FP receptors in the eye.…”

mentioning

confidence: 99%

See 1 more Smart Citation

New Fluoroprostaglandin F2.ALPHA. Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents

Nakajima

Matsugi

Goto

et al. 2003

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

An elevated intraocular pressure (IOP) is one of the risk factors for the development of glaucoma. Recent prospective epidermal studies in the United States indicate that if IOP is lowered below 12 mmHg, 1) or by more than 30% from the baseline IOP in patients with normal-tension glaucoma, 2) the progress of the visual field defect can be delayed. Prostaglandin (PG) derivatives exert ocular-hypotensive effects through stimulation of prostanoid receptors (FP, DP, IP etc.) and possibly by activation of signal-transduction systems such as intracellular Ca 2ϩ and cyclic AMP. [3][4][5][6] One of the most potent PGF 2a derivatives at reducing IOP is latanoprost, a selective prostanoid FP-receptor agonist, and this drug has been successfully developed as an anti-glaucoma agent. 7) Recently, another selective prostanoid FP-receptor agonist, travoprost, was launched in the United States and other countries.8) Because of their potent, long-lasting ocular-hypotensive effects, prostanoid FP-receptor agonists are widely used for the treatment of glaucoma.However, clinical use over several years has revealed the existence of patients who do not respond well to PGF 2a derivatives. 9,10) In addition, long-term application of PGF 2a derivatives causes chronic adverse effects, such as iris/skin pigmentation, eyelash growth, and so on. [10][11][12][13][14][15][16][17][18][19] The PGF 2a -derivative-induced eye colour change is most likely due to an increased amount of melanin within iris stroma melanocytes. [20][21][22] These adverse effects may be related to the stimulation of prostanoid FP receptors in the eye. 3)To judge from the accumulating findings relating to latanoprost and other PGF 2a derivatives, prostanoid FP-receptor agonists are among the most promising ocular-hypotensive agents. To try to find prostanoid FP-receptor agonists that might be more potent at inducing an IOP reduction while causing fewer or weaker side effects than latanoprost, we synthesized new PGF 2a derivatives and evaluated their prostanoid FP-receptor-mediated activities both in vitro and in vivo. We report here some interesting new compounds with fluorine(s) in the 15-position of the PGF 2a -derivative structure. MATERIALS AND METHODS Materials Prostarumon® F injection 1000 (1 mg/ml PGF 2a ) was obtained from Ono Pharmaceutical Co., Ltd. (Osaka, Japan), while cloprostenol was from Cayman Chemical Co. (Ann Arbor, MI, U.S.A.). Latanoprost free acid, latanoprost, and free acid and ester forms of various PGF 2a derivatives (Table 1) Constriction of the Isolated Iris Sphincter in CatsA functional prostanoid FP-receptor-affinity assay was performed using iris sphincter muscles isolated from cat eyes. 23)This tissue expresses predominantly prostanoid FP receptors. 24,25) Male European cats (Charles River Japan, Kanagawa, Japan) weighing from 2.5 to 5.0 kg were sacrificed by injection of intravenous sodium pentobarbital (Dainippon Pharmaceutical Co., Ltd., Osaka, Japan). The eyes were immediately enucleated and placed into modified Krebs-Henseleit sol...

show abstract

Section: Discussionsupporting

confidence: 82%

mentioning

confidence: 99%

New Fluoroprostaglandin F2.ALPHA. Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents

Nakajima

Matsugi

Goto

et al. 2003

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…23 However, previous clinical trials with latanoprost monotherapy, another prostaglandin analogue, have established a long-lasting daytime hypotensive effect with little evidence of tachyphylaxis, for up to 4 years. [24][25][26][27][28] This is further corroborated by the present long-term 24-hour study, which documented consistent IOP efficacy with travoprost monotherapy in POAG patients during the 5-year follow-up period.…”

Section: Discussionsupporting

confidence: 70%

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Riva

Katsanos

Floriani

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

Purpose: The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients.Patients and Methods: A total of 36 previously untreated primary open-angle glaucoma patients were enrolled in this 5-year study.Patients underwent an untreated 24-hour IOP evaluation. Subsequently all patients were assigned to topical therapy with travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered once in the evening (8:00 PM) in both eyes. All patients were then scheduled for a 24-hour IOP assessment approximately 12 months after the baseline visit. This schedule of follow-up was maintained for the whole duration of the trial. The predetermined range of target IOP reduction selected in this cohort of patients ranged between 20% and 30%.Results: A total of 34 patients completed all phases of the investigation. The mean survival time was 57.3 ± 2.0 months and the cumulative survival rate was 0.82 ± 0.6 at 60 months. Travoprost reduced the mean 24-hour IOP from 23.4 ± 1.7 mm Hg at baseline to 16.8 ± 2.4 mm Hg (28.4%), 16.8 ± 2.5 mm Hg (28.1%), 16.8 ± 2.4 mm Hg (28.5%), 16.7 ± 2.5 mm Hg (28.6%), and 16.9 ± 2.4 mm Hg (27.8%), respectively at the end of the first, second, third, fourth, and fifth year follow-up. No drug-related serious adverse events were registered during the study.Conclusions: The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma.Key Words: open-angle glaucoma, prostaglandin analogue, circadian intraocular pressure, travoprost (J Glaucoma 2014;23:535-540) R eduction of intraocular pressure (IOP) is the only currently available, evidence-based management strategy in patients affected with primary open-angle glaucoma (POAG). Most POAG patients will require lifelong medical therapy to avoid visual loss. The decision to select medical therapy options relies primarily on the efficacy of the available medications in various therapeutic trials. Sadly, most published studies only evaluate the short-term, daytime efficacy of medical therapy.Prostaglandin analogues have become a popular firstline therapy option for lowering IOP in POAG owing to their superior 24-hour efficacy, 1-6 convenient once-a-day administration, 5 and favorable systemic safety profile. 7 Travoprost is a synthetic prostaglandin F2a analogue that exerts its IOP-lowering effect through the prostaglandin FP receptors situated at the ciliary muscle 8 and the trabecular meshwork. 9 Travoprost is increasingly becoming a popular first-line monotherapy option for POAG patients 10 as there is cumulative evidence suggesting good quality of shortterm 24-hour IOP control with low fluctuation, especially with evening administration. 11-13 However, although several controlled studies have demonstrated the daytime short-term efficacy of travoprost monotherapy, [14][15][16] little is currently known about its long-term efficacy.As POA...

show abstract

“…4,5 The fixed combination of timolol and latanoprost, marketed as Xalacom ® in Europe, became commercially available in 2001 and was heralded by a series of short-term studies examining its efficacy, safety and tolerability. This article summarises the evidence to date on fixed-combination timolol/latanoprost and looks at the future for this fixed-combination glaucoma preparation.…”

mentioning

confidence: 99%

Long-term Efficacy and Safety of Fixed-combination Timolol/Latanoprost

Harding¹,

Montgomery²

2009

European Ophthalmic Review

View full text Add to dashboard Cite

The fixed-combination preparation of timolol and latanoprost has been available in Europe since 2001. Evidence supporting its level of clinical efficacy has been slowly accumulating, with some studies suggesting clear benefit and others showing only a modest additional effect relative to its individual components. Studies demonstrating long-term protection of visual function are sparse and more work is required in this area. Several reports indicate that fixed-combination timolol/latanoprost is safe and well tolerated. Other similar combination products are now competing directly with fixed-combination timolol/latanoprost, and further comparative studies will be required to assess their relative merits. KeywordsFixed combination, prostaglandin analogue, beta-blocker, adverse effects, efficacy, protection In devising the 'ideal' glaucoma drop, it is almost intuitive that a combination preparation of two monotherapies should be a Holy Grail in the treatment of glaucoma. Indeed, the benefits seem clear: better patient compliance, fewer daily dosages and therefore fewer adverse effects, ideally synergy of the active components, less exposure to excipients, lower cost and effective intraocular pressure (IOP) control.The concept of combining individual glaucoma drugs is not new. although there is some evidence that the conventional outflow pathway is also involved. 7 Its mode of action is thought to involve the induction of matrix metalloproteinases (MMPs) in the ciliary body smooth muscle and possibly also in ciliary melanocytes. [8][9][10] MMPs then break down the ciliary body extracellular matrix and reduce hydraulic resistance to uveoscleral outflow. Meanwhile, timolol acts at β-adrenergic receptors in the ciliary body to decrease production of aqueous humour, 11 but its exact mode of action remains unclear.

show abstract

Latanoprost: Experience of 2‐year treatment in Scandinavia

Abstract: ABSTRACT.Purpose: The aim of the study was to assess efficacy and side effects of latanoprost during two years of treatment.

Cited by 63 publications

References 8 publications

New Fluoroprostaglandin F2.ALPHA. Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents

New Fluoroprostaglandin F2.ALPHA. Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Long-term Efficacy and Safety of Fixed-combination Timolol/Latanoprost

Contact Info

Product

Resources

About